Skip to main content
. 2021 Jan 6;219:108486. doi: 10.1016/j.drugalcdep.2020.108486

Fig. 2.

Fig. 2

A/B/C. Number of Unique Patients Dispensed Buprenorphine, Extended-Release Naltrexone, and Naloxone, United States, January 2019 – May 2020*.

A. Number of Unique Patients Dispensed Buprenorphine

Source: IQVIA Total Patient Tracker

CI = Confidence Interval

*Prescription dispensing amounts that fell above or below the 95 % CI are considered statistically significant

B. Number of Unique Patients Dispensed Extended-release (ER) Intramuscular Naltrexone*

Source: IQVIA Total Patient Tracker

ER = Extended-Release

CI = Confidence Interval

*Prescription dispensing amounts that fell above or below the 95 % CI are considered statistically significant

C. Number of Unique Patients Dispensed Naloxone*

Source: IQVIA Total Patient Tracker

CI = Confidence Interval

*Prescription dispensing amounts that fell above or below the 95 % CI are considered statistically significant